Topic: monoclonal antibody
The SuperHuman library contains over 5,000 hits against each of the 26 Distributed Bio targets in immunology and neurodegeneration.
Y-mAbs Therapeutics raised $50 million from private investors to fund late-stage trials of two antibodies with potential in treatment of rare cancers.
J&J is now assessing what it will take to quell the FDA’s concerns about the safety of the IL-6 monoclonal antibody before deciding on a path forward.
Arcus inked an $816 million deal for a PD-1 drug developed by Chinese firms WuXi Biologics and Gloria Pharmaceuticals.
Ten years after taking over Agensys in a $537 million deal, Japan's Astellas has decided to pull the plug on the Santa Monica-based operation.
Eli Lilly likes what it sees in Adimab's antibody R&D platform, opting to roll it out at sites in San Diego and New York to help its antibody discovery and optimization activities.
Harvard professor Timothy Springer spoke to FierceBiotechResearch about the new Institute for Protein Innovation, which he created to further the development of antibodies targeting proteins that reside outside of cell walls.
Infectious disease specialist Arsanis has raised a solid chunk of cash as it picks up the Gates Foundation and Alphabet's GV as backers.
Prothena is celebrating some positive early-stage data from a Roche-partnered program that aims to find a disease-modifying therapy for Parkinson's disease.